Clinical Cardiology Alert – June 1, 2009
June 1, 2009
View Archives Issues
-
Coronary CT Angiography to Rule Out Acute Coronary Syndromes in the Emergency Department
Patients presenting to the emergency department (ED) with acute chest pain are a significant portion of our health care budget. Current recommendations for the assessment and management of these patients involve extended periods of observation for repeated biomarkers and electrocardiograms (ECG). This often results in hospital admission to "rule out" myocardial infarction. Any advance in the speed or accuracy of diagnosis of the cause of chest pain, or to rule out myocardial ischemia as the cause, would be a significant clinical advance. -
Continuous ECG Monitoring for Detection of Ischemia After ACS
After acute coronary syndromes (ACS), re-currence of ischemia is a harbinger of worse prognosis. -
CRP in Pulmonary Hypertension
New markers for a variety of diseases have recently received considerable attention, specifically B-type natriuretic peptide (BNP), N-terminal-pro-BNP, C-reactive protein, or CRP, and CRP-hs (high sensitivity). Levels of these compounds are useful guides in assessing the severity of important medical conditions, such as congestive heart failure and acute myocardial infarction chest pain. -
Syncope and Hypertrophic Cardiomyopathy
Syncope is commonly accepted to be a danger sign in patients with hypertrophic cardiomyopathy (HCM). In this paper, Spirito et al report data from a registry of 1,511 patients with HCM who have been followed longitudinally at four institutions. -
Valsartan for Atrial Fibrillation?
It has been postulated that angiotensin-converting enzyme (ACE) inhibitors and angiotensin II-receptor blockers (ARBs) decrease the risk of developing atrial fibrillation both indirectly by better control of hypertension and heart failure and directly by effects on fibrosis, -
Clinical Briefs in Primary Care Supplement
-
Pharmacology Watch
NSAIDs in the elderly; managing GI and CVD risk with NSAIDs; low-dose naltrexone and fibromyalgia; treating glucocorticoid-induced bone loss; FDA Actions.